Future research should include comparative studies and evaluate if TFF3 and I-FABP could effectively be used to improve risk stratification of children with SM and determine whether other less invasive samples beyond peripheral blood (for instance, stool) could be used to ascertain biomarker levels and subsequent risk. This evidence concerns the gene FABP2 and systemic mastocytosis.